Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 5:33 pm Purchase |
2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Ikarian Capital, LLC | 1,191,957 9.990% |
221,598 (+22.84%) |
Filing History |
| 2025-05-15 5:26 pm Purchase |
2025-03-31 | 13G | Traws Pharma, Inc. TRAW |
Ikarian Capital, LLC | 589,502 9.990% |
195,247 (+49.52%) |
Filing History |
| 2025-05-15 5:26 pm Purchase |
2025-03-31 | 13G | Cumberland Pharmaceuticals Inc. CPIX |
Ikarian Capital, LLC | 730,932 4.900% |
730,932 (New Position) |
Filing History |
| 2025-02-14 1:25 pm Purchase |
2024-12-31 | 13G | Avenue Therapeutics, Inc. ATXI |
Ikarian Capital, LLC | 140,000 6.800% |
140,000 (New Position) |
Filing History |
| 2025-02-14 1:22 pm Purchase |
2024-12-31 | 13G | Galera Therapeutics, Inc. GRTX |
Ikarian Capital, LLC | 7,538,690 9.990% |
7,538,690 (New Position) |
Filing History |
| 2025-02-14 1:21 pm Purchase |
2024-12-31 | 13G | Aethlon Medical, Inc. AEMD |
Ikarian Capital, LLC | 1,229,285 8.700% |
1,229,285 (New Position) |
Filing History |
| 2025-02-14 1:18 pm Purchase |
2024-12-31 | 13G | Traws Pharma, Inc. TRAW |
Ikarian Capital, LLC | 394,255 9.990% |
394,255 (New Position) |
Filing History |
| 2025-02-14 1:15 pm Purchase |
2024-12-31 | 13G | Forte Biosciences, Inc. FBRX |
Ikarian Capital, LLC | 609,225 9.500% |
609,225 (New Position) |
Filing History |
| 2025-02-14 1:09 pm Purchase |
2024-12-31 | 13G | Channel Therapeutics Corporation CHRO |
Ikarian Capital, LLC | 440,849 7.300% |
440,849 (New Position) |
Filing History |
| 2025-02-14 1:07 pm Purchase |
2024-12-31 | 13G | Alpha Cognition Inc. Common Stock ACOG |
Ikarian Capital, LLC | 967,867 6.000% |
967,867 (New Position) |
Filing History |
| 2024-11-14 8:51 pm Purchase |
2024-09-30 | 13G | TRACON Pharmaceuticals, Inc. TCON |
Ikarian Capital, LLC | 133,404 3.900% |
133,404 (New Position) |
Filing History |
| 2024-11-14 8:47 pm Purchase |
2024-09-30 | 13G | iBio, Inc. IBIO |
Ikarian Capital, LLC | 599,913 6.600% |
599,913 (New Position) |
Filing History |
| 2024-10-07 8:06 pm Purchase |
2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX |
Ikarian Capital, LLC | 970,359 10.020% |
970,359 (New Position) |
Filing History |
| 2024-04-05 4:10 pm Purchase |
2024-03-31 | 13G | TRACON Pharmaceuticals, Inc. TCON |
Ikarian Capital, LLC | 133,547 5.900% |
133,547 (New Position) |
Filing History |
| 2024-02-14 6:00 pm Unchanged |
2023-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM |
Ikarian Capital, LLC | 448,101 4.600% |
0 (Unchanged) |
Filing History |
| 2023-02-14 12:57 pm Purchase |
2022-12-31 | 13G | TRACON Pharmaceuticals, Inc. TCON |
Ikarian Capital, LLC | 138,277 12.500% |
3,721 (+2.77%) |
Filing History |
| 2023-02-14 11:26 am Sale |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Ikarian Capital, LLC | 11,638 0.300% |
-63,845 (-84.58%) |
Filing History |
| 2023-02-14 11:03 am Sale |
2022-12-31 | 13G | Milestone Pharmaceuticals Inc. MIST |
Ikarian Capital, LLC | 460,416 1.300% |
-1,289,627 (-73.69%) |
Filing History |
| 2023-02-14 11:02 am Sale |
2022-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM |
Ikarian Capital, LLC | 448,101 5.200% |
-48,655 (-9.79%) |
Filing History |
| 2022-02-14 4:43 pm Sale |
2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
Ikarian Capital, LLC | 75,483 8.100% |
-12,017 (-13.73%) |
Filing History |